Subscribe
Logo small
Search

Positive recommendations for pharizymab. Patient communities: it's another chance to save sight

MedExpress Team

Piotr Wójcik

Published July 12, 2023 11:08

Positive recommendations for pharizymab. Patient communities: it's another chance to save sight - Header image
Thinkstock/GettyImages
The Transparency Council and the President of the AOTMiT have issued positive recommendations for the addition of pharizymab therapy to the drug program for retinal diseases. - This is an opportunity, especially for those patients for whom the drugs used so far do not bring the desired result, comments Anna Sliwinska, president of the Polish Diabetes Association.

Retinal diseases are one of the leading causes of visual impairment and loss worldwide. Some of these diseases may be hereditary, while others may be related to age, diabetes or other diseases. Among the most common diseases are age-related macular degeneration (AMD) and diabetic macular edema (DME).

Treatment of retinal diseases is provided under a combined drug program, as the same therapies are used for both conditions. They involve the administration of a drug by injection into the vitreous chamber of the eye. Such injections are initially given every 4 weeks for 3 months, and then the frequency of injections is adjusted according to the type of condition, the effecti...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie o pracę za darmo

Lub znajdź wyjątkowe miejsce pracy!

Read also